Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Biocon Limited
  6. Summary
    BIOCON   INE376G01013

BIOCON LIMITED

(BIOCON)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
364.4(c) 360.4(c) 370.7(c) 367.5(c) 366.85(c) Last
2 513 989 4 131 254 3 496 010 5 011 584 2 610 184 Volume
+0.44% -1.10% +2.86% -0.86% -0.18% Change
More quotes
Estimated financial data (e)
Sales 2022 80 759 M 1 073 M 1 073 M
Net income 2022 7 482 M 99,4 M 99,4 M
Net Debt 2022 28 742 M 382 M 382 M
P/E ratio 2022 55,5x
Yield 2022 0,28%
Sales 2023 100 B 1 333 M 1 333 M
Net income 2023 12 800 M 170 M 170 M
Net Debt 2023 28 293 M 376 M 376 M
P/E ratio 2023 33,8x
Yield 2023 0,37%
Capitalization 436 B 5 799 M 5 799 M
EV / Sales 2022 5,76x
EV / Sales 2023 4,63x
Nbr of Employees 13 500
Free-Float 35,3%
More Financials
Company
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and... 
More about the company
Ratings of Biocon Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about BIOCON LIMITED
12/02Biocon Arm Gets US FDA Nod for Mycophenolic Acid
MT
12/02Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
AQ
11/18Biocon to Offer Insulin Glargine Injection Through Walgreens Prescription Savings Club
MT
11/17Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE (insulin glargi..
AQ
11/16Biocon Biologics Launches Insulin Glargine Injections in US
MT
11/16Viatris Inc. and Biocon Biologics Ltd. Announces Launch of Interchangeable Semglee? (In..
CI
11/15Indian shares gain on pharma, banking boost; Nykaa drops over 7%
RE
11/05Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchange..
AQ
10/22BIOCON : announced its consolidated financial results for the second quarter ended Septemb..
AQ
10/22BIOCON : Posts Drop in Q2 Consolidated Net Profit
MT
10/21Biocon Limited Announces Revenue Guidance for the Full Financial Year 2022
CI
10/21Biocon Limited Reports Earnings Results for the Second Quarter and Six Months Ended Sep..
CI
10/21BIOCON : Biologics First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed wi..
AQ
10/21Indian stocks inch lower as tech losses outweigh energy gains
RE
10/20Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
RE
More news
News in other languages on BIOCON LIMITED
12/02Le bras de Biocon obtient le feu vert de la FDA pour l'acide mycophénolique
11/18Biocon proposera l'injection d'insuline Glargine dans le cadre du Walgreens Prescriptio..
11/16Biocon Biologics lance les injections d'insuline glargine aux États-Unis
11/15Les actions indiennes progressent grâce à l'essor des secteurs pharmaceutique et bancai..
10/22Biocon enregistre une baisse de son bénéfice net consolidé au deuxième trimestre.
More news
Chart BIOCON LIMITED
Duration : Period :
Biocon Limited Technical Analysis Chart | BIOCON | INE376G01013 | MarketScreener
Technical analysis trends BIOCON LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 366,85 INR
Average target price 365,94 INR
Spread / Average Target -0,25%
EPS Revisions
Managers and Directors
Siddharth Mittal Chief Executive Officer, Director & MD
Indranil Sen Chief Financial Officer
Kiran Mazumdar-Shaw Executive Chairman
Manoj Kumar Pananchukunnath Head-Regulatory Sciences, Research & Development
Sandeep Nilkanth Athalye Head-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOCON LIMITED-21.18%5 799
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819